恒瑞醫藥(01276.HK):悉數行使超額配股權、穩定價格行動及穩定價格期間結束
格隆匯6月19日丨恒瑞醫藥(01276.HK)宣佈,招股章程所述的超額配股權已於2025年6月19日(星期四)獲整體協調人(為其本身及代表國際承銷商)悉數行使,涉及合共33,677,800股H股,相當於全球發售項下初步可供認購的發售股份總數(於行使超額配股權前)的約15%。
超額配發股份將由公司按每股H股44.05港元發行及配發。超額配發股份將用於促成向已同意延遲交付其根據全球發售認購的部分H股的承配人交付相關H股。
根據香港法例第571W章《證券及期貨(穩定價格)規則》第9(2)條,公司宣佈,全球發售的穩定價格期間於2025年6月19日(星期四)(即提交香港公開發售申請的截止日期後第30日)結束。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.